Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768558 · ClinicalTrials.gov registry record · Phase 3
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
A Phase 3 study, sponsored by RTOG Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT02768558: Clinical Trial Phase 3 study, sponsored by RTOG Foundation.
NCT02768558 is a Phase 3 study that was terminated before completion, run by RTOG Foundation. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02768558, a Phase 3 study, was terminated before completion, sponsored by RTOG Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
Primary Outcome
Survival time is defined as time from registration to date of death from any cause and was to be estimated by the Kaplan-Meier method. Given the limited follow-up due to early closure and termination of data collection, only the number of patients last reported to be alive at time of study termination is reported and no statistical testing was done.
Interventions
- DRUG Cisplatin
- OTHER Placebo
- DRUG Nivolumab
- DRUG Etoposide
- RADIATION Radiation Therapy (RT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 3 |
Why NCT02768558 stopped before completion
NCT02768558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02768558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02768558 about?
NCT02768558 is a clinical study titled "Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC". Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
What is the current status of trial NCT02768558?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2016-10-17. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT02768558?
The interventions under investigation include: Cisplatin (DRUG), Placebo (OTHER), Nivolumab (DRUG), Etoposide (DRUG), Radiation Therapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT02768558?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02768558's enrollment target sits among peer trials
20 1956th of 2000 higher than 32 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI